Acurx Pharmaceuticals, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Selling, general & administrative | — | — | — | — | $208,270 |
| Research and development | $1.8M | $5.4M | $6.0M | $4.8M | $2.0M |
| Operating expenses | $8.1M | $14.1M | $14.6M | $12.1M | $12.8M |
| Operating income | -$8.1M | -$14.1M | — | — | — |
| Income tax expense | — | — | — | $0 | — |
| Net income | -$8.0M | -$14.1M | -$14.6M | -$12.1M | -$12.7M |
| Balance Sheet | |||||
| Total assets | $7.7M | $3.9M | $7.7M | $9.4M | $13.3M |
| Current liabilities | $2.4M | $3.2M | $3.0M | $2.1M | $843,909 |
| Total liabilities | $2.4M | $3.2M | $3.0M | $2.1M | $843,909 |
| Stockholders' equity | $5.3M | $615,121 | $4.7M | $7.3M | $12.4M |
| Cash Flow Statement | |||||
| Cash from operations | -$6.8M | -$10.4M | -$9.8M | -$7.5M | -$5.0M |
| Stock-based compensation | $1.2M | $2.6M | $3.2M | $2.9M | $5.2M |
Shares outstanding 4.3M · Free float 37.7%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.